Mayo Clinic Proceedings Home

Sea Change for Marine Omega-3s

Randomized Trials Show Fish Oil Reduces Cardiovascular Events
Published:October 15, 2019DOI:https://doi.org/10.1016/j.mayocp.2019.04.027

      Abstract

      Recently, 3 large randomized controlled trials (RCTs) have assessed the effects of supplementation with marine omega-3 fatty acids on the occurrence of cardiovascular disease (CVD) events. We reviewed this evidence and considered it in the context of the large and growing body of data on the CV health effects of marine omega-3s. One RCT examining 8179 patients, most with coronary heart disease (CHD), reported that 4 grams/day of a highly purified omega-3 product containing eicosapentaenoic acid (EPA) reduced the risk for major adverse CV events by 25% ( P<.001). Two other recent RCTs in primary prevention populations showed that approximately 1 gram/day of purified fish oil containing 840 mg/day of EPA and docosahexaenoic acid (DHA) significantly reduced risks of CHD and CV death, especially in individuals who did not consume fish and seafood frequently. The American Heart Association (AHA) continues to emphasize the importance of marine omega-3s as a nutrient for potentially reducing risks of congestive heart failure, CHD, ischemic stroke, and sudden cardiac death. Marine omega-3s should be used in high doses for patients with CHD on statins who have elevated triglycerides and at about 1 gram/day for primary prevention for individuals who do not consume at least 1.5 fish or seafood meals per week.

      Abbreviations and Acronyms:

      AFIB ( atrial fibrillation), AHA ( American Heart Association), ALA ( α-linolenic acid), CHD ( coronary heart disease), CV ( cardiovascular), CVD ( cardiovascular disease), DHA ( docosahexaenoic acid), DPA ( docosapentaenoic acid), EPA ( eicosapentaenoic acid), hsCRP ( high-sensitivity C-reactive protein), HR ( hazard ratio), IPE ( icosapent ethyl), LDL-C ( low-density lipoprotein cholesterol), LV ( left ventricle), LVESVI ( left ventricular end-systolic volume index), LVEF ( ventricular eject faction), MRI ( magnetic resonance imaging), MACE ( major adverse CV events), MI ( myocardial infarction), O-3FA ( omega-3 fatty acids), PUFA ( polyunsaturated fatty acid), RBC ( red blood cell), RCT ( randomized controlled trial), TG ( triglyceride)
      To read this article in full you will need to make a payment

      References

        • Bang H.O.
        • Dyerberg J.
        • Nielsen A.B.
        Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos.
        Lancet. 1971; 1: 1143-1145
        • Bhatt D.L.
        • Steg P.G.
        • Miller M.
        • et al.
        Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
        N Engl J Med. 2018; 380: 11-22
        • Manson J.E.
        • Cook N.R.
        • Lee I.M.
        • et al.
        Marine n-3 fatty acids and prevention of cardiovascular disease and cancer.
        N Engl J Med. 2018; 380: 23-32
        • Bowman L.
        • Mafham M.
        • Wallendszus K.
        • et al.
        Effects of n-3 fatty acid supplements in diabetes mellitus.
        N Engl J Med. 2018; 379: 1540-1550
        • Barter P.J.
        • Caulfield M.
        • Eriksson M.
        • et al.
        Effects of torcetrapib in patients at high risk for coronary events.
        N Engl J Med. 2007; 357: 2109-2122
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 373: 2387-2397
        • Landray M.J.
        • Haynes R.
        • et al.
        • HPS2-THRIVE Collaborative Group
        Effects of extended-release niacin with laropiprant in high-risk patients.
        N Engl J Med. 2014; 371: 203-212
        • Boden W.E.
        • Probstfield J.L.
        • et al.
        • AIM-HIGH Investigators
        Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
        N Engl J Med. 2011; 365: 2255-2267
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376: 1713-1722
        • Szarek M.
        • White H.D.
        • Schwartz G.G.
        • et al.
        Alirocumab reduces total nonfatal cardiovascular and fatal events in the ODYSSEY OUTCOMES trial.
        J Am Coll Cardiol. 2019; 73: 387-396
        • Marso S.P.
        • Daniels G.H.
        • Brown-Frandsen K.
        • et al.
        Liraglutide and cardiovascular cutcomes in type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322
        • Zinman B.
        • Wanner C.
        • Lachin J.M.
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Bowman L.
        • Chen F.
        • et al.
        • REVEAL Collaborative Group
        Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL): A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: trial design, recruitment, and baseline characteristics.
        Am Heart J. 2017; 187: 182-190
        • Jiang Y.
        • Tan H.C.
        • Tam W.W.S.
        • Lim T.W.
        • Wang W.
        A meta-analysis on omega-3 supplements in preventing recurrence of atrial fibrillation.
        Oncotarget. 2018; 9: 6586-6594
        • Nordestgaard B.G.
        Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology.
        Circ Res. 2016; 118: 547-563
        • Nichols G.A.
        • Phillip S.
        • Reynolds K.
        • Granowitz C.B.
        • Fazio S.
        Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol.
        J Clin Endocrinol Metab. 2018; 103: 3019-3027
        • Ganda O.P.
        • Bhatt D.L.
        • Mason R.P.
        • Miller M.
        • Boden W.E.
        Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management.
        J Am Coll Cardiol. 2018; 72: 330-343
        • Lavie C.J.
        • DiNicolantonio J.J.
        • Milani R.V.
        • O'Keefe J.H.
        Niacin therapy lives for another day–maybe?.
        J Am Coll Cardiol. 2013; 61: 2197-2198
        • Wang D.
        • Liu B.
        • Tao W.
        • Hao Z.
        • Liu M.
        Fibrates for secondary prevention of cardiovascular disease and stroke.
        Cochrane Database Syst Rev. 2015; 10: CD009580
        • Malur P.
        • Menezes A.
        • DiNicolantonio J.J.
        • O'Keefe J.H.
        • Lavie C.J.
        The microvascular and macrovascular benefits of fibrates in diabetes and the metabolic syndrome: a review.
        Mo Med. 2017; 114: 464-471
        • Skulas-Ray A.C.
        • Kris-Etherton P.M.
        • Harris W.S.
        • Vanden Heuvel J.P.
        • Wagner P.R.
        • West S.G.
        Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.
        Am J Clin Nutr. 2011; 93: 243-252
        • Kim C.H.
        • Han K.A.
        • Lee S.H.
        • et al.
        Efficacy and safety of adding omega-3 fatty acids in statin-treated patients with residual hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a randomized, double-blind, and placebo-controlled trial.
        Clin Ther. 2018; 40: 83-93
        • Miller M.
        • Stone N.J.
        • Ballantyne C.M.
        • et al.
        Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
        Circulation. 2011; 123: 2292-2333
        • DiNicolantonio J.J.
        • O'Keefe J.H.
        Importance of maintaining a low omega-6/omega-3 ratio for reducing inflammation.
        Open Heart. 2018; 5: e000946
        • Akintoye E.
        • Sethi P.
        • Harris W.S.
        • et al.
        Fish oil and perioperative bleeding: insights from the OPERA randomized trial.
        Circ Cardiovasc Qual Outcomes. 2018; 11: e004584
        • Harris W.S.
        Expert opinion: omega-3 fatty acids and bleeding-cause for concern?.
        Am J Cardiol. 2007; 99: 44C-46C
        • Alexander D.D.
        • Miller P.E.
        • Van Elswyk M.E.
        • Kuratko C.N.
        • Bylsma L.C.
        A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk.
        Mayo Clin Proc. 2017; 92: 15-29
        • Burr M.L.
        • Fehily A.M.
        • Gilbert J.F.
        • et al.
        Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART).
        Lancet. 1989; 2: 757-761
        • Harris W.S.
        • Del Gobbo L.
        • Tintle N.L.
        The Omega-3 Index and relative risk for coronary heart disease mortality: estimation from 10 cohort studies.
        Atherosclerosis. 2017; 262: 51-54
        • Tavazzi L.
        • Maggioni A.P.
        • Marchioli R.
        • et al.
        Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 1223-1230
        • O'Keefe J.H.
        • Jacob D.
        • Lavie C.J.
        Omega-3 fatty acid therapy: the tide turns for a fish story.
        Mayo Clin Proc. 2017; 92: 1-3
        • Aung T.
        • Halsey J.
        • Kromhout D.
        • et al.
        Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77,917 individuals.
        JAMA Cardiol. 2018; 3: 225-234
        • Del Gobbo L.C.
        • Imamura F.
        • Aslibekyan S.
        • et al.
        Omega-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies.
        JAMA Intern Med. 2016; 176: 1155-1166
        • Siscovick D.S.
        • Barringer T.A.
        • Fretts A.M.
        • et al.
        Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association.
        Circulation. 2017; 135: e867-e884
        • O'Keefe Jr., J.H.
        • Abuissa H.
        • Sastre A.
        • Steinhaus D.M.
        • Harris W.S.
        Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions.
        Am J Cardiol. 2006; 97: 1127-1130
        • Harris W.S.
        • von Schacky C.
        The Omega-3 Index: a new risk factor for death from coronary heart disease?.
        Prev Med. 2004; 39: 212-220
        • Harris W.S.
        • Sands S.A.
        • Windsor S.L.
        • et al.
        Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation.
        Circulation. 2004; 110: 1645-1649
        • Metcalf R.G.
        • Cleland L.G.
        • Gibson R.A.
        • et al.
        Relation between blood and atrial fatty acids in patients undergoing cardiac bypass surgery.
        Am J Clin Nutr. 2010; 91: 528-534
        • GISSI-Preventione-Investigators
        Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo studio della Sopravvivenza nell’infarto miocardico.
        Lancet. 1999; 354: 447-455
        • Walker R.E.
        • Jackson K.H.
        • Tintle N.L.
        • et al.
        Predicting the effects of supplemental EPA and DHA on the omega-3 index.
        Am J Clin Nutr. 2019; 110: 1034-1040
        • Yokoyama M.
        • Origasa H.
        • Matsuzaki M.
        • et al.
        Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
        Lancet. 2007; 369: 1090-1098
        • Heydari B.
        • Abdullah S.
        • Pottala J.V.
        • et al.
        Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial.
        Circulation. 2016; 134: 378-391
        • Middleton P.
        • Gomersall J.C.
        • Gould J.F.
        • Shepherd E.
        • Olsen S.F.
        • Makrides M.
        Omega-3 fatty acid addition during pregnancy.
        Cochrane Database Syst Rev. 2018; 11: CD003402
        • Rimm E.B.
        • Appel L.J.
        • Chiuve S.E.
        • et al.
        Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association.
        Circulation. 2018; 138: e35-e47
        • Blasko I.
        Interaction of ω-3 fatty acids with B vitamins in slowing the progression of brain atrophy: identifying the elderly at risk.
        Am J Clin Nutr. 2015; 102: 7-8
        • Mason R.P.
        • Dawoud H.
        • Jacob R.F.
        • Sherratt S.C.R.
        Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin.
        Biomed Pharmacother. 2018; 103: 1231-1237
        • Mehra M.R.
        • Lavie C.J.
        • Ventura H.O.
        • Milani R.V.
        Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure.
        J Heart Lung Transplant. 2006; 25: 834-838
        • Kris-Etherton P.M.
        • Harris W.S.
        • Appel L.J.
        Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.
        Circulation. 2002; 106: 2747-2757
        • Millen B.
        • Lichtenstein A.H.
        • Abrams S.
        • et al.
        2015-2020 Dietary Guidelines for Americans.
        8th Ed. US Department of Agriculture, Washington, DC2015
        • Hedengran A.
        • Szecsi P.B.
        • Dyerberg J.
        • Harris W.S.
        • Stender S.
        n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial.
        Lipids. 2015; 50: 165-175
        • Mason R.P.
        • Sherratt S.C.R.
        Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits.
        Biochem Biophys Res Commun. 2017; 483: 425-429
        • Zibaeenezhad M.J.
        • Ghavipisheh M.
        • Attar A.
        • Aslani A.
        Comparison of the effect of omega-3 supplements and fresh fish on lipid profile: a randomized, open-labeled trial.
        Nutr Diabetes. 2017; 7: 1